Frontlight ResearchEarly access
Enrolling by invitationPhase 1
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
Key facts
- Who runs it
- Changchun BCHT Biotechnology Co.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 1
- People taking part
- 144 people, planned
- Started
- 13 Oct 2025
- Expected to end
- Jun 2027
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Low-Dose Cohort
- Mid-Dose Cohort
- High-Dose Cohort
- Placebo Group
- Record updated
- 9 January 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (25)Hide the full registry criteria
Who can take part
- Is a healthy male or female aged 18 to 55 years (inclusive) at the time of screening
- Has provided written informed consent prior to performing any study-specific procedure
- Is available and willing to comply with all study procedures for the entire duration of the study
- For participants of childbearing potential: agrees to practice highly effective contraception for the required period and has no plans for reproduction or gamete donation
- Provides consent for HSV-1/HSV-2 serology testing at screening
Who cannot take part
- History of clinically diagnosed genital herpes within 6 months prior to the first vaccination
- Acute infectious disease or acute exacerbation of a chronic condition within 3 days prior to screening/vaccination
- History of severe allergic reactions requiring medical intervention (e.g., anaphylaxis, angioedema, Arthus reaction, allergic purpura), severe adverse reactions to previous vaccinations, or known hypersensitivity to any component of the investigational vaccine (e.g., lipid nanoparticles)
- Use of immunosuppressants or immunomodulators (e.g., systemic corticosteroids for >14 consecutive days) or cytotoxic therapy within 6 months prior to the first vaccination, or planned use during the study
- Administration of blood products or immunoglobulins within 3 months prior to the first vaccination or planned use during the study
- Treatment with anti-herpetic drugs (e.g., acyclovir, valacyclovir, famciclovir, ganciclovir) for genital herpes within 6 months prior to the first vaccination
- Receipt of live-attenuated vaccines within 14 days, or subunit/inactivated vaccines within 7 days prior to vaccination
- Participation in another clinical trial (drug, device, or vaccine) within 3 months prior to the first vaccination or concurrent enrollment in any interventional study
- Known or suspected malignancy, autoimmune disease, immunodeficiency, organ transplantation, or immunosuppression (e.g., HIV infection, systemic lupus erythematosus [SLE], rheumatoid arthritis)
- Congenital anomalies or developmental disorders affecting organ function
- History of cardiovascular diseases (e.g., myocardial ischemia, myocardial infarction, myocarditis, pericarditis, idiopathic cardiomyopathy, arrhythmias), or any condition increasing the risk of myocarditis/pericarditis; QTcF >450 ms for males or >470 ms for females; or uncontrolled hypertension (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg despite medication)
- Contraindications to intramuscular injection (e.g., thrombocytopenia, coagulation disorders)
- Medical conditions requiring intervention affecting the endocrine, hematologic, hepatic, renal, respiratory, metabolic, or skeletal systems
- History of convulsions (excluding febrile seizures in childhood), epilepsy, encephalopathy, psychiatric disorders, or other neurological conditions; or family history of psychiatric disorders
- Positive markers for HBV, HCV, HIV, or syphilis infection
- Any other condition deemed by the investigator to compromise participant safety or interfere with study objectives
- Axillary temperature >37.0°C during screening and/or on the day of vaccination
- Positive blood pregnancy test at screening or currently breastfeeding (for female participants)
- For HSV-1/HSV-2 seronegative participants: clinically significant abnormalities in hematology, blood biochemistry, coagulation, or urinalysis parameters at screening
- For HSV-1/HSV-2 seropositive participants: hematology, blood biochemistry, coagulation, or urinalysis parameters ≥ Grade 1 per the study-specific toxicity grading scale and deemed clinically significant by the investigator
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Genital herpes
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus
The 4 groups in the trial
- PlaceboPlacebo, for comparison
Treatment: Placebo Group
- Low-DoseTreatment being tested
HSV-2 mRNA Vaccine
Treatment: Low-Dose Cohort
- Mid-DoseTreatment being tested
HSV-2 mRNA Vaccine
Treatment: Mid-Dose Cohort
- High-DoseTreatment being tested
HSV-2 mRNA Vaccine
Treatment: High-Dose Cohort
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) in Healthy Participants Aged 18-55 Years, Stratified by Serostatus
- Criteria questions
- Built from NCT07330440, who can take part
- Record updated
- 9 January 2026